Cronos stock climbs after launching Peace Naturals medical cannabis brand in Germany
The U.S.-listed shares of Cronos Group Inc. (CRON.T) climbed 2.5% in premarket trading Monday, after the Toronto-based cannabis company said it launched its Peace Naturals medical brand in Germany. The company has signed a distribution agreement with Cansativa Group, which has a network of about 2,000 pharmacies in Germany. Cronos said it expects the recently announced regulatory changes in Germany, in which cannabis is no longer labeled a narcotic, to "unlock significant growth" in Germany. "Re-entering the German market, which has about 83 million people, is a significant milestone for Cronos and we look forward to expanding our reach and brand awareness in Germany with the help of Cansativa," said Cronos Chief Executive Mike Gorenstein. The stock has soared 39.8% over the past three months through Friday, while the AdvisorShares Pure US Cannabis ETF (MSOS) has jumped 65.5% and the S&P 500 has gained 0.9%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-18-23 0747ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now